MADRIGAL PHARMACEUTICALS, INC. Revenue from Contract with Customer, Excluding Assessed Tax in USD from 2022 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Madrigal Pharmaceuticals, Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from 2022 to Q3 2025.
  • Madrigal Pharmaceuticals, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending September 30, 2025 was $287M, a 362% increase year-over-year.
  • Madrigal Pharmaceuticals, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending September 30, 2025 was $741M.
  • Madrigal Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $180M.
  • Madrigal Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $0.000.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)

MADRIGAL PHARMACEUTICALS, INC. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $741M $287M +$225M +362% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 $516M $213M +$198M +1354% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $317M $137M +$137M Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 $180M $103M Oct 1, 2024 Dec 31, 2024 10-K 2025-02-26
Q3 2024 $62.2M +$62.2M Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $14.6M +$14.6M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $0 Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q3 2023 $0 Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $0 Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07

MADRIGAL PHARMACEUTICALS, INC. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $180M +$180M Jan 1, 2024 Dec 31, 2024 10-K 2025-02-26
2023 $0 $0 Jan 1, 2023 Dec 31, 2023 10-K 2025-02-26
2022 $0 Jan 1, 2022 Dec 31, 2022 10-K 2025-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.